Vosoritide approved for treatment of linear growth in pediatric patients with achondroplasia: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG).
作者信息
Poskanzer Sheri A, Peña Loren D M, Niu Zhiyv
机构信息
St. Luke's Health System, Boise, ID.
Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
出版信息
Genet Med Open. 2023 Mar 27;1(1):100771. doi: 10.1016/j.gimo.2023.100771. eCollection 2023.
Abstract
摘要
相似文献
1
Vosoritide approved for treatment of linear growth in pediatric patients with achondroplasia: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG).伏索瑞肽获批用于治疗小儿软骨发育不全患者的线性生长：美国医学遗传学与基因组学学会（ACMG）的一份治疗公告
Genet Med Open. 2023 Mar 27;1(1):100771. doi: 10.1016/j.gimo.2023.100771. eCollection 2023.
2
Consensus Guidelines for the Use of Vosoritide in Children with Achondroplasia in Australia.澳大利亚使用伏索瑞肽治疗软骨发育不全儿童的共识指南。
Children (Basel). 2024 Jun 28;11(7):789. doi: 10.3390/children11070789.
3
Vosoritide Therapy in Children with Achondroplasia: Early Experience and Practical Considerations for Clinical Practice.成骨不全症患儿中使用 vosoritide 的治疗：早期经验和临床实践中的实际考虑。
Adv Ther. 2024 Jan;41(1):198-214. doi: 10.1007/s12325-023-02705-9. Epub 2023 Oct 26.
4
Olipudase alfa approved for pediatric and adult patients with acid sphingomyelinase deficiency (ASMD): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG).olipudase alfa获批准用于治疗患有酸性鞘磷脂酶缺乏症（ASMD）的儿科和成人患者：美国医学遗传学与基因组学学会（ACMG）的治疗公报
Genet Med Open. 2023 Apr 17;1(1):100780. doi: 10.1016/j.gimo.2023.100780. eCollection 2023.
5
Expert consensus for the management of patients with achondroplasia in treatment with vosoritide.关于使用维索瑞肽治疗软骨发育不全患者的专家共识。
An Pediatr (Engl Ed). 2024 Dec;101(6):401-410. doi: 10.1016/j.anpede.2024.09.012. Epub 2024 Dec 6.
6
Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery.一项随机、对照、开放性临床试验的原理、设计和方法，以及开放性扩展，旨在研究 vosoritide 在有颈椎髓减压手术风险的软骨发育不全婴儿和幼儿中的安全性。
Sci Prog. 2021 Jan-Mar;104(1):368504211003782. doi: 10.1177/00368504211003782.
7
Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial.每日一次，皮下注射 vosoritide 治疗软骨发育不全患儿：一项随机、双盲、3 期、安慰剂对照、多中心试验。
Lancet. 2020 Sep 5;396(10252):684-692. doi: 10.1016/S0140-6736(20)31541-5.
8
Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.成骨不全症患儿中 vosoritide 的安全且持续的促生长作用：一项开放标签、3 期扩展研究的 2 年结果。
Genet Med. 2021 Dec;23(12):2443-2447. doi: 10.1038/s41436-021-01287-7. Epub 2021 Aug 2.
9
Approach to the Patient with Achondroplasia-New Considerations for Diagnosis, Management, and Treatment.软骨发育不全患者的诊疗方法——诊断、管理及治疗的新思考
J Clin Endocrinol Metab. 2025 Jun 17;110(7):e2309-e2316. doi: 10.1210/clinem/dgaf017.
10
Two Cases of Cardiovascular Adverse Events Following Subcutaneous Vosoritide Injection in Early Infancy.婴儿早期皮下注射伏索瑞肽后发生心血管不良事件两例
Cureus. 2024 May 5;16(5):e59695. doi: 10.7759/cureus.59695. eCollection 2024 May.
引用本文的文献
1
Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence.用于治疗软骨发育不全的沃索瑞肽（Voxzogo）：临床及真实世界证据综述
Cureus. 2025 Jul 15;17(7):e87983. doi: 10.7759/cureus.87983. eCollection 2025 Jul.
本文引用的文献
1
Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia.成骨不全症患儿伏索利肽的药代动力学和暴露-反应关系。
Clin Pharmacokinet. 2022 Feb;61(2):263-280. doi: 10.1007/s40262-021-01059-1. Epub 2021 Aug 25.
2
Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.成骨不全症患儿中 vosoritide 的安全且持续的促生长作用：一项开放标签、3 期扩展研究的 2 年结果。
Genet Med. 2021 Dec;23(12):2443-2447. doi: 10.1038/s41436-021-01287-7. Epub 2021 Aug 2.
3
In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia.成纤维细胞生长因子受体 3 可溶性蛋白（Recifercept）治疗软骨发育不全症的体外和体内特性研究
PLoS One. 2020 Dec 28;15(12):e0244368. doi: 10.1371/journal.pone.0244368. eCollection 2020.
4
Health Supervision for People With Achondroplasia.成骨不全症患者的健康监督
Pediatrics. 2020 Jun;145(6). doi: 10.1542/peds.2020-1010.
Zotero 插件